ARTL - Latest News
Artelo Biosciences, Inc. (ARTL), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.1M. Beta to the broader market is -0.07.
The article list below shows the most recent ARTL headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ARTL Headlines
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
globenewswire.com - Oct 7, 2026
Presentation to feature results from first clinical study of ART26.
Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in September
defenseworld.net - Oct 1, 2026
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a large decrease in short interest during the month of September.
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
globenewswire.com - Sep 23, 2026
As reported, ART27.
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
globenewswire.com - Sep 16, 2026
Once-daily, oral ART27.
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 36.9% in August
defenseworld.net - Aug 31, 2026
Artelo Biosciences, Inc. (NASDAQ: ARTL - Get Free Report) saw a significant decline in short interest in the month of August.
How News Affects ARTL Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ARTL's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ARTL news questions
- What is the latest ARTL news headline?
- The most recent ARTL headline (Oct 7, 2026) is "Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ARTL news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ARTL news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ARTL options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.